Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.30 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4759713 | 0.92 | PIK3CG (0.35) | HCAR3AOC3 | |
| SCHEMBL2689466 | 0.87 | GPR119 (0.35) | — | |
| SCHEMBL4759715 | 0.83 | PIK3CG (0.39) | ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL12598913 | 0.83 | NPC1 (0.35) | HCAR3AOC3TRPV1ALDH1A1MAPK1 | |
| SCHEMBL2690998 | 0.78 | LMNA (0.34) | — | |
| SCHEMBL2690337 | 0.77 | LMNA (0.35) | — | |
| SCHEMBL2690832 | 0.75 | OGA (0.38) | — | |
| SCHEMBL4759337 | 0.75 | LMNA (0.38) | HCAR3 | |
| SCHEMBL12598911 | 0.75 | ALDH1A1 (0.36) | HCAR3AOC3ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL2688914 | 0.74 | PIK3CG (0.46) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9243000-B2 | Thia-triaza-indacenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-26 | — | — | US | disclosed |
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108618-A1 | THIA-TRIAZA-INDACENES | CCNA1, MKI67, CCNT1 | HCAR3 4031/4885AOC3 2844/4885CXCR1 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.